•	_	10/717653			
•	ATTY, DOCKET NO.	APPLICATION NO.			
	4821-529-999	Not yet assigned			
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT				
(Use several sheets if necessary)	T. Jerussi				
	FILING DATE	GROUP			
	Herewith	To be assigned			

	U.S. PATENT DOCUMENTS							(
*EXAMI NITU	*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
al		AA	6,127,363	10/2000	Doherty et al.			
	\perp	AB	6,174,925	01/2001	Bailey et al.			
	\perp	AC	6,046,242	11/1998	Emmelmann			
	\perp	AD	5,795,880	08/1998	Svec et al.			·
		AE	5,780,051	07/1998	Eswara et al.			
	Ш	AF	5,733,566	03/1998	Lewis	•		
	Ш	AG	5,719,283	02/1998	Bell et al.			
		АН	5,674,553	10/1997	Shinoda et al.			
		Al	5,639,476	06/1997	Oshlack et al.			
		AJ	5,591,767	01/1997	Mohr et al.			
		AK	5,552,429	09/1996	Wong et al.			
		AL	5,459,164	10/1995	Vargas			
		AM	5,436,272	07/1995	Scheinbaum			
		AN	5,354,556	10/1994	Sparks et al.			
	$oxed{oxed}$	AO	5,250,534	10/1993	Bell et al.			
		AP	5,120,548	06/1992	McClelland et al.			
		AQ	5,104,899	04/1992	Young et al.			
		AR	5,073,543	12/1991	Marshall et al.			
		AS	5,068,440	11/1991	Jeffery et al.	- -		
1		AT	5,059,595	10/1991	Le Grazie	·		
\longrightarrow		AU	4,988,814	01/1991	Abou-Gharbia et al.			
		AV	4,939,175	07/1990	Ukai et al.			
		AW	4,929,629	05/1990	Jeffery			
		AX	4,871,774	10/1989	Rees			
		AY	4,816,488	03/1989	Rees			
		AZ	4,814,352	03/1989	Jeffery et al.			
		ВА	4,806,570	02/1989	Jeffery et al.			
		BB	4,746,680	05/1988	Jeffery et al.			
		вс	4,552,828	11/1985	Toya et al.			
		BD	4,522,828	06/1985	Jeffery et al.			
		BE	4,008,719	02/1977	Theeuwes et al.			
w		BF	3,960,891	06/1976	Malen et al.			

ly Lis

- 2		•	,			T			<u> </u>
<u>(e)</u>	\perp	BG	3,916,899	11/1975	Theeuwes et al.				
		вн	3,845,770	11/1974	Theeuwes et al.				
	\perp	ВІ	3,598,123	08/1971	Zaffaroni				
<u> </u>	\perp	ВЈ	3,536,809	10/1970	Applezweig				
<u> </u>		вк	3,471,515	10/1969	Troxler et al.			<u> </u>	
		BL	3,155,670	11/1964	Janssen et al.			<u> </u>	
		вм	3,155,669	11/1964	Janssen et al.				
				FORE	IGN PATENT DOCUMENTS				
			DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	NO
		BN	WO 00/56322	09/2000	PCT			763	-NY
		во	WO 00/56321	09/2000	PCT				
		ВР	WO 00/56318	09/2000	PCT			,	
		BQ	WO 00/56315	09/2000	PCT				
		BR	WO 00/56314	09/2000	РСТ				
		BS	WO 00/56309	09/2000	PCT				
		вт	WO 00/56306	09/2000	PCT				
		BU	WO 00/56151	09/2000	PCT				
		BV.	WO 00/56150	09/2000	PCT				·
		BW	WO 00/56149	09/2000	PCT				
		вх	WO 00/56148	09/2000	PCT			-	
		BY	WO 00/54765	09/2000	PCT				
		BZ	WO 00/32182	11/1998	PCT				
		CA	WO 99/33450	07/1999	PCT				
		СВ	WO 98/13034	04/1998	PCT				
		СС	WO 98/13033	04/1998	PCT				
		CD	WO 98/11884	03/1998	PCT				
		CE	WO 98/06722	02/1998	PCT				
		CF	EP 0 781 561 A1	07/1997	EPO				
		CG	WO 97/20810	06/1997	PCT			×	
		СН	WO 97/03675	02/1997	PCT				
		CI	WO 95/21615	08/1995	PCT				
		ည	WO 95/20949	08/1995	PCT				
		ск	WO 94/28902	12/1994	PCT				
		CL	WO 94/00114	01/1994	PCT				
\coprod		СМ	WO 94/00047	01/1994	PCT				
		CN	WO 90/06110	06/1990	PCT				
\sqcup		со	WO 88/06444	09/1988	PCT				·
1		СР	DE 32 12 682 A1	10/1982	Germany				
lac	\Box	CQ	GB 2098602 A	11/1982	United Kingdom				

ay do

æl	1	CR	ED 0 025 507	0/1094	Europa	т -		Γ	
W	+	CR	EP 0 035 597	9/1981	Europe	<u></u>	<u> </u>	<u> </u>	L
	T	cs	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) CS. Paldagagain et al. Life Sciences 39: 1765-1777 (1996)						
	+-	"	Baldessarini et al., <i>Life Sciences</i> 39: 1765-1777, (1986). Buckett et al., "BTS 54 524-An Approach to Rapidly Acting Antidepressant," <i>New Concepts in Depression</i>						
	\perp	СТ	2: 167-172 (1988).		oach to Rapidly Acting Antidepressant," N	ew Cond	epts in De	epressic)N — —
		cu			Sibutramine Hydrochloride (BTS 54 524), -Regulation", <i>Prog. Neuro-Psychopharmac</i>				hich
	↓_	cv	Buckett et al., "Sibutrar	mine Hydroch	lloride," Drugs of the Future 13(8): 736-738	3 (1988).			
	\bot	cw	Butler, D., Facile Cyclos	alkylation of A	rylacetonitriles in Dimethyl Sulfoxide, J. Org	. Chem.	36:1308-	1309 (1	971)
		сх	Canonne, P., et al., <i>Eff</i> 21:155-58 (1980)	et du Benzen	e Dans la Reaction de Grignard sur les Nit	riles, Te	trahedron	Lett.,	
		CY	Carstensen, J., Drug S	tability: Princ	ciples & Practice, 2d. Ed., pp. 379-80, Marc	el Dekk	er, NY, N	Y, (1995	5).
		cz	Castello, R.A., et al., <i>L</i> (1962)	Discoloration	of Tablets Containing Amines and Lactos	e, Phan	n. Sci. 51	(2):106	-108
		DA			ne Binding in Rat Frontal Cortex Strongly (/arious Antidepressant Treatments, Neuro				8),
		DB			nethoxyphenyl)-piperazin-1-yl)-2-phenylpro ic and Postsynaptic 5-HT _{1A} Receptors, Med				
		DC	Diagnostic and Statistic (1997).	cal Manual of	Mental Disorders, Fourth Ed., American P	sychiatri	c Associa	ation,	
		DD	Diagnostic and Statistic	cal Manual of	Mental Disorders, 3rd Ed., American Psyc	hiatric A	ssociatio	n (1981)).
		DE	Dreshfield et al., Enhar	ncement of Fl ngonist at 5-H	luoxetine-Dependent Increase of Extracello T _{1A} Receptors, Neurochem. Res., 21(5):55	ılar Serc 57-562 (1	tonin (5-H 1996)	IT) Leve	∍ls
		DF	Eliel, E.L., Stereochem	istry of Carbo	on Compounds (McGraw-Hill, NY, 1962).				
		DG	Evans et al., "Prevalen 262: 2551-2556 (1989)		ner's Disease in a Community Population o	f Older I	Persons,"	J.A.M.A	l. ·
		DH			e apparent anti-depressant activity of (-) an 85: 7, page 31, No. 40768t (1976).	id (+) tra	nylpromin	e in an	
		DI	Goodman & Gilman, Tl	he Pharmaco	logical Basis of Therapeutics, 362-373, 40	4 (9 th ed	. McGraw	-Hill, 19	96)
		DJ			Opioidergic System in the Antinociceptive I Pharmacol., Vol. 124, No. 4, (1998) pp 669		sm of Acti	on of	
-	T	DK	Handbook of Pharmace	eutical Excipi	ents, 2 nd ed., Wade and Willer eds., pp. 25	7-259 (1	994)		
		DL			ects on Central 5-HT Function of Sibutrami armacol. (1998), 125(2), 301-308	ine Hydr	ochloride	and Oth	ner
		DM	Hillver et al., (S)-5-Fluc Med. Chem., 33:1541-4		r-2-(dipropylamino)tetralix: A Putative 5-H7	1A Recej	otor Antag	onist, J	
		DN	J. Med. Chem., Vol. 36		0 (1993)				
		DO	Introduction to Pharma	ceutical Dosa	age Forms, 4th ed., Lea & Febiger, Philade	lphia (19	985).	· · · · · · ·	
		DP			nates and Resolutions," (Wiley-Interscience	`			.
	1	DQ			ical Sciences, 78: 9: 695-715 (1989)				
a	t	DR	Jeffery et al., Synthesis	of Sibutrami	ine, A Novel Cyclobutylalkylamine Useful in Chem. Soc. Perkin. Trans. 1, 2583-2589 (atment of	Obesit	у.
						/			

ay Li

	•	
Ola	DS	King et al., "Clinical Pharmacology of Sibutramine Hydrochloride (BTS 54524) A New Antidepressant, in Healthy Volunteers," Clinical Pharmac. 26: 607-611 (1989).
	DT	Kula et al., "Effects of N-Substituted Phenyltetrahydropyridines on Cerebral High-Affinity Synatosomal Uptake of Dopamine and Other Monoamines in Several Mammalian Species," Life Sciences 34(26): 2567-2575, (1984).
	DU	Luscombe et al., The Contribution of Metabolites to the Rapid and Potent Down-Regulation of Rat Cortical β-Adrenoceptors by the Putative Antidepressant Sibutramine Hydrochloride, Neuropharmacology, Vol. 28, No. 2, (1989) pp 129-134
	DV	The Merck Manual of Diagnosis and Therapy, ??th Ed., Merck & Co., Inc., Whitehouse Station, NJ, (1999).
	DW	Middlemiss et al., Centrally Active 5-HT Receptor Agonists and Antagonists, Neurosci. and Biobehv. Rev., 16:75-82 (1992)
	DX	Moreau et al., Behavioral Profile of the 5-HT _{1A} Receptor Antagonist (S)-UH-301 in Rodents and Monkeys, Brain Res. Bull., 29:901-04 (1992)
	DY	Nakada et al., An Enantioconvergent Route to (-)-Kainic Acid, Tetrahedron Lett., 38:857-860 (1997)
	DZ	Physician's Desk Reference® 473-475 (53rd ed., 1999)
	EA	Physician's Desk Reference® 475-476 (53 rd ed., 1999)
	EB	Physician's Desk Reference® 764-766 (53 rd ed., 1999)
	EC	Physician's Desk Reference® 823-825 (53 rd ed., 1999)
	ED	Physician's Desk Reference® 978-979 (53 rd ed., 1999)
	EE	Physician's Desk Reference® 1054-1056 (53™ ed., 1999)
	EF	Physician's Desk Reference® 1332-1334 (53 rd ed., 1999)
	EG	Physician's Desk Reference® 1369-1370 (53 rd ed., 1999)
	EH	Physician's Desk Reference® 1432-1436 (53™ ed., 1999)
	EI	Physician's Desk Reference® 1494-1498 (53 rd ed., 1999)
	EJ	Physician's Desk Reference® 1641-1645 (53™ ed., 1999)
	EK	Physician's Desk Reference® 2004-2009 (53 rd ed., 1999)
	EL	Physician's Desk Reference® 2075-2078 (53™ ed., 1999)
	EM	Physician's Desk Reference® 2190-2192 (53 rd ed., 1999)
	EN	Physician's Desk Reference® 2367-2368 (53rd ed., 1999)
	EO	Physician's Desk Reference® 2396-2399 (53rd ed., 1999)
	EP	Physician's Desk Reference® 2490-2493 (53 rd ed., 1999)
	EQ	Physician's Desk Reference® 2516-2521 (53rd ed., 1999)
	ER	Physician's Desk Reference® 2688-2691 (53rd ed., 1999)
	ES	Physician's Desk Reference® 2701-2704 (53rd ed., 1999)
	ET	Physician's Desk Reference® 2720-2726 (53rd ed., 1999)
	EU	Physician's Desk Reference® 2735-2736 (53 rd ed., 1999)
	EV	Physician's Desk Reference® 2886-2888 (53rd ed., 1999)
	EW	Physician's Desk Reference® 2908-2910 (53rd ed., 1999)
	EX	Physician's Desk Reference® 3092-3094 (53rd ed., 1999)
ac	EY	Physician's Desk Reference® 3101-3104 (53rd ed., 1999)

ail	? i	EZ	Physician's Desk Reference® 3224-3225 (53 rd ed., 1999)
		FA	Physician's Desk Reference® 3267-3272 (53rd ed., 1999)
		FB	Physician's Desk Reference® 3307-3309 (53 rd ed., 1999)
		FC	Physician's Desk Reference® 3383-3384 (53 rd ed., 1999)
	ļ	FD	Physician's Desk Reference® 2520 (52 nd ed., 1998)
	į,	FE	Physician's Desk Reference® 2958 (52 nd ed., 1998)
		FF	Remingtons: The Practice of TheScience and Pharmacy, 19th ed., Gennaro, ed., p. 1625 (1995)
		FG	Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton PA (1990).
		FH	Remington's Pharmaceutical Sciences, 16th ed., Mack Publishing, Easton PA (1980).
		FI	Stock, M.J., Sibutramine: A Review of the Pharmacology of a Novel Anti-Obesity Agent, Int'l J. Obesity, 21(Supp. 1):S25-S29 (1997)
		FJ	U.S. Pharmocopia (USP) SP (XXI)/NF (XVI) Jan 1, 1985
		FK	Wilen et al., Tetrahedron, 2725-36 33(21) (1977).
a	ℓ	FL	Wilen, S.H., Tables of Resolving Agents and Optical Resolutions 268 (E.L. Eliel ed., Univ. of Notre Dame Press, Notre Dame, IN, 1972).
EXAM	INER	R	Qy 29 DATE CONSIDERED 5/19/06
*EVAL	415151	7. Initial	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.